Annual Indirect Economic Burden of Sickle Cell Disease Over $2 Million
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 13, 2024 -- Adults with sickle cell disease (SCD) are more likely to report employment loss, and caregivers of children with SCD report more missed days of work, according to a study published online Feb. 29 in Blood Advances.
Rachel D'Amico Gordon, M.D., from The Ohio State University College of Medicine in Columbus, and colleagues examined the indirect economic burden of SCD and assessed whether socioeconomic status and greater social vulnerability risks are associated with increased absenteeism and employment loss. Adults with SCD and caregivers of children with SCD at five U.S. centers were surveyed.
The researchers found that 10.3 and 17.5 percent of the 244 participants reported employment loss in the last five years and missing 10 or more days of work, respectively. Compared with caregivers of children with SCD, adults with SCD had three times more employment loss (odds ratio, 3.18), but fewer missed days of work (odds ratio, 0.24). Increased employment loss and more missed days of work were reported for participants who did not live with a partner (odds ratios, 4.70 and 4.58, respectively). The estimated indirect economic burden was $2,266,873 per year ($9,290 per participant).
"The impact of medical care costs compounded by losses of income opportunities perpetuate a vicious cycle of poverty among many patients with SCD and their families," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.